Immunological Data Discovery Index
Advanced Search
identifier: 1903647
description:
epitope description:A: W72, F150, A151; B: T214, R215, F216, A220, S221, K222, C255, Q256, G257, K258, N317, F318, L348, G349, T350, L351, D367, V380, S381, Q382, S383, G384
antigen name:Proprotein convertase subtilisin/kexin type 9
host organism:Mus musculus Xenomouse
antibody name:mAb1
aggregation:
instance of dataset
availability:
available
primaryPublications: 19443683
authorizations:
registration not required
accessURL: http://www.iedb.org/reference/1019641
landingPage: http://www.iedb.org/assay/1903647
type:
Literature
publicationVenue:
Proc Natl Acad Sci U S A
dates:
2009
study type: b cell assays
subject species: Homo sapiens
fullName:
Joyce C Y Chan
Derek E Piper
Qiong Cao
Dongming Liu
Chadwick King
Wei Wang
Jie Tang
Qiang Liu
Jared Higbee
Zhen Xia
Yongmei Di
Susan Shetterly
Ziva Arimura
Heather Salomonis
William G Romanow
Stephen T Thibault
Richard Zhang
Ping Cao
Xiao-Ping Yang
Timothy Yu
Mei Lu
Marc W Retter
Gayle Kwon
Kirk Henne
Oscar Pan
Mei-Mei Tsai
Bryna Fuchslocher
Evelyn Yang
Lei Zhou
Ki Jeong Lee
Mark Daris
Jackie Sheng
Yan Wang
Wenyan D Shen
Wen-Chen Yeh
Maurice Emery
Nigel P C Walker
Bei Shan
Margrit Schwarz
Simon M Jackson
method:
biological activity
name:
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates.
description:
Epitope residues are calculated from the structure [PDB: 3H42] as the antigen residues at 4 Å
distance from the antibody. Chains A and B in the structure belong to the same polypeptide chain (Chain A: residues 31-152 constitute the prodomain and Chain B: 153-692
residues 153-454 constitute the catalytic domain, and residues 455-692 constitute the C-terminal domain).
The epitope-specific monoclonal antibody inhibited PCSK9 activity as measured by increased LDLR expression. The monoclonal antibody also inhibited binding of PCSK9 to LDLR.

Feedback?

If you are having problems using our tools, or if you would just like to send us some feedback, please post your questions on Feedback.